IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4048
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$47M
Shaun R. Bagai
RenovoRx, Inc. focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$RNXT RenovoRx, Inc. | 36 | 32 | 27 | 33 | - | - | -132.4% | -95.5% | 80.0% | -1837.9% | -1596.3% | - | 0.0% | 39.0x | $47M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
RenovoRx, Inc. (RNXT) receives a "Avoid" rating with a composite score of 35.6/100. It ranks #4048 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Shaun R. Bagai
Chief Executive Officer
Labor Force
6
32
25
51
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for RNXT
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for RNXT.
View All RatingsHigh margin volatility — erratic forensic earnings quality
ROE proxy -132.4% (sector -2.5%)
GM 80% vs sector 43%, OM -1838% vs sector 1%
Capital turnover N/A, R&D intensity 811.1%
Rev growth N/A, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags RenovoRx, Inc. with an Avoid rating, assigning a composite score of 35.6/100 and 1 out of 5 stars. Ranked #4048 of 7,333 stocks, RNXT falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
RNXT's quality score of 32/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -132.4% (sector avg: -2.5%), gross margins of 80.0% (sector avg: 42.5%), net margins of -1596.3% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
RNXT registers a value score of just 27/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 4.13x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
RenovoRx, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -95.5% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
RNXT is currently showing below-average momentum at 33/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.79 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 51/100, RNXT exhibits average financial resilience. Key stability metrics include a beta of 0.79 and a debt-to-equity ratio of 39.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 53/100 for RNXT suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 39.00x), micro-cap liquidity risk. With a $47M market cap (micro-cap), RenovoRx, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
RenovoRx, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4048 of 7,333 overall (45th percentile). Key comparisons include ROE of -132.4% trailing the -2.5% sector median and operating margins of -1837.9% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While RNXT currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (25) would have the largest impact on the composite score.
ROE 5240% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 88% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 142571% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate RenovoRx, Inc. (RNXT) as Avoid with a composite score of 35.6/100 at a current price of $0.98. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in stability (51th percentile) and momentum (33th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (25th percentile) and value (27th percentile) tempers our overall conviction. We assign a No Moat rating (32/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
RenovoRx, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.6/100 places it at rank #4048 in our full 7,333-stock universe. At $47M in market capitalization, RenovoRx, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (33th percentile) suggest caution regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
The margin cascade tells an important story: gross margins of 80% (+37.5pp vs sector) narrow to operating margins of -1838% (-1839.2pp vs sector) and net margins of -1596.3%, yielding a gross-to-net conversion rate of -1995%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.98, RenovoRx, Inc. is trading at a premium to fundamental value. Our value factor score of 27/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 4.1x, P/S of 56.9x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 80% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
The Avoid rating (composite 35.6/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -1596.3% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (33th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (32th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Medium uncertainty rating to RenovoRx, Inc.. The stock presents a balanced risk profile: current negative profitability (net margin -1596.3%) and weak quality scores (32th percentile). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: current negative profitability (net margin -1596.3%); weak quality scores (32th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 51th percentile and quality factor at the 32th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 80% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate RenovoRx, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-132.4%), negative profitability, weak asset returns (ROA -95.5%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — RenovoRx, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, RenovoRx, Inc. receives a Avoid rating with a composite score of 35.6/100 (rank #4048 of 7,333). Our quantitative framework assigns a No Moat (32/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 33/100.
Our analysis does not support a constructive view on RenovoRx, Inc. at this time. The combination of limited competitive advantages, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign RenovoRx, Inc. a meaningful economic moat, scoring 32/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10.2/20.
The strongest moat sources are margin superiority (10.2/20) and financial resilience (8.1/20). GM 80% vs sector 43%, OM -1838% vs sector 1%. Interest coverage N/A. These pillars form the core of RenovoRx, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and growth durability (4.2/20). ROE proxy -132.4% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect RenovoRx, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 80% providing a solid profitability foundation. The margin cascade from 80% gross to -1838% operating to -1596.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 32th percentile.
The margin profile shows gross margins of 80%, operating margins of -1838%, net margins of -1596.3%. Return metrics include ROE of -132.4% and ROA of -95.5%. Relative to the Manufacturing sector, gross margins are 37.5 percentage points above the sector median of 43%, and ROE of -132.4% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 39%. The sector median D/E is 0%, putting RenovoRx, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Appointment Strengthens RenovoRx’s C-Suite Leadership to Support Commercial Growth of RenovoCath®MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company’s Chief Financial Officer, effective February 1, 2026. Mr. Voll b
Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-DeliveryMOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that new clinical data will be presente
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical DataMOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that its abstract submission to the 2026 Soci
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Longboard Pharmaceuticals shares jumped 199.7% to $18.07 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Akso Health Group (NASDAQ: AHG) surged 85% to $1.2946. Polished.com Inc. (NYSE: POL) gained 45% to $8.77. Dogness (International) Corporation (NASDAQ: DOGZ) jumped 40% to $7.42. Cue Health Inc. (NASDAQ: HLTH) gained 36.8% to $0.2224 after falling 42% on Friday. Voyager Therapeutics, Inc. (NASDAQ: VYGR) surged 34% to $11.38 after the company announced a strategic collaboration and capsid license agreement with Novartis to advance potential gene therapies for Huntington's disease and spinal muscular atrophy. RiskOn International, Inc. (NASDAQ: ROI) shares climbed 33.5% to $0.4450 after gaining around 17% on Friday. RiskOn International recently said it expects to announce its new generative AI platform and unveil a principal technology partner on Jan. 3. Soligenix, Inc. (NASDAQ: SNGX) shares gained 33.4% to $1.01. Soligenix announced publication demonstrating complete protection against filovirus disease in nonhuman primate models of ebola and marburg viruses. SenesTech, Inc. (NASDAQ: SNES) gained 22.2% to $1.56. SenesTech announced the expansion of its distribution agreement with Pesterminators Pvt Ltd to include the deployment of EvolveTM. Brooge Energy Limited (NASDAQ: BROG) jumped 17.1% to $4.31. Brooge Energy recently announced that it reached a settlement with the SEC where it agreed to pay a $5 million penalty and cease any future violations. Lyell Immunopharma, Inc. (NASDAQ: LYEL) gained 16.9% to $2.26. Wheels Up Experience Inc. (NYSE:
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. DouYu plans repurchase of up to $20 million of ordinary shares in the form of ADSS during period of up to twelve months commencing on Jan. 1, 2024. DouYu International shares jumped 14.2% to $0.8320 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Nova LifeStyle, Inc. (NASDAQ: NVFY) shares jumped 204% to $4.71. Cingulate Inc. (NASDAQ: CING) climbed 157.4% to $10.27. On Tuesday, Cingulate received FDA guidance for CTx-1301 (dexmethylphenidate), its lead investigational product candidate for attention deficit hyperactivity disorder (ADHD). Bone Biologics Corporation (NASDAQ: BBLG) gained 62.2% to $7.54. SenesTech, Inc. (NASDAQ: SNES) shares climbed 50.7% to $1.30. HC Wainwright & Co. analyst Amit Dayal maintained SenesTech with a Buy, adjusting target to $3.5 from $4. Microbot Medical Inc. (NASDAQ: MBOT) rose 38% to $1.8301 after the company announced the completion of its GLP pivotal pre-clinical study. Sidus Space, Inc. (NASDAQ: SIDU) gained 32% to $5.81. DatChat, Inc. (NASDAQ: DATS) rose 30% to $2.62. DatChat announced the release of its new AI social gaming platform and developer program for game designers and content creators. SEALSQ Corp (NASDAQ: LAES) gained 25% to $1.4424. SEALSQ disclosed that its post-quantum semiconductor technology, based on cutting-edge cryptographic algorithms, is specifically designed to withstand attacks from and secure cryptocurrency transactions against the looming threat of quantum computing. Ocean Biomedical, Inc. (NASDAQ: OCEA) surged 21.4% to $0.7299. DSS, Inc. (NYSE: DSS) jumped 21% to $0.1477. RenovoRx, Inc. (NASDAQ: RNXT) gained 20% to $1.2599. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) rose 20% to $3.6250. The FDA recently approved the company's Zoryve topical foam, 0.3% for seborrheic dermatitis in individuals nine years and older. Envoy ...